32 Biosciences
About this raise
32 Biosciences, with a valuation of $31.25 million, is raising funds on Republic. It is a diversified life science company focused on harnessing microbiome science to prevent and treat diseases. 32 Biosciences is taking a new approach to medicine to build clinically useful and validated tools to diagnose and correct Dysbiosis or microbiome imbalance. The offerings of 32 Biosciences include a gut microbiome diagnostic tool and targeted microbiome therapeutics and has collaborations with academic institutions and business partners. John Alverdy, Eugene B. Chang, and Joseph F. Pierre founded 32 Biosciences in June 2023. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for research and development, operations, manufacturing, and regulatory expenses.
Investment Overview
Invested : $508,898
Deal Terms
Total Commitments
- Platform
- Republic
- Start Date
- 06/24/2024
- Close Date
- 12/20/2024
$50,000
$618,000
$300
SAFE
Early Stage
RegCF
$31,250,000
20%
Company & Team
Company
- Year Founded
- 2023
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- High
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of FY2023
- Monthly Burn
-
$25,000
as of FY2023
-
Runway
-
9 months
as of
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $1,652,516
- Grants
- $2,300,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Republic | $31,250,000 | $508,898 | SAFE | Funded | RegCF |
Founder Interview
What Investors Want to Know: How 32 Biosciences is Transforming Microbiome Medicine
32 Biosciences has the potential to help millions of Americans fight chronic diseases. Peter Farmakis,CEO, tells us more about his vision for the company.